This study is designed to assess the efficacy and safety of de-escalating dual antiplatelet therapy (DAPT) at 1 month compared to the standard 12 months of therapy in patients undergoing percutaneous coronary intervention (PCI) guided by intravascular ultrasound (IVUS). The main outcomes measured will include major adverse cardiovascular and cerebrovascular events (NACCE), bleeding events, and target vessel failure (TVF). The goal is to evaluate whether a shorter duration of DAPT is non-inferior to the standard 12-month regimen in preventing ischemic events while reducing the incidence of bleeding.
Patients aged 18 years or older.
Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
Unstable Angina: Prolonged chest pain at rest, new-onset angina within the past 2 months, or increasing frequency/severity of angina attacks.
Acute Myocardial Infarction (MI): With or without ST-elevation.
Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.
Neurological Complications: Stroke or any permanent neurological deficits within the last 3 months.
Coronary Artery Bypass Graft Surgery: History of CABG surgery.
Planned Surgery: Patients who have surgeries planned within the next 12 months.
University Medical Center Ho Chi Minh City (UMC)
Lead sponsor
University of Medicine and Pharmacy at Ho Chi Minh City
Sponsor institution
University of Medicine and Pharmacy at Ho Chi Minh City
Collaborator